How to research a manufacturer across FDA names
Check applicant and recalling-firm names without confusing spelling variations, subsidiaries, and unrelated companies.
Read the guide →Medical-device intelligence
Research Immco Diagnostics, Inc. in public FDA records: applicant and recalling-firm names, product codes, clearance history, and recall records.
This profile groups matching applicant and recalling-firm names found in covered FDA records. It does not imply a complete corporate family, current ownership, or every product marketed under a brand.
55 clearance records and 0 recall records in the covered releases, across 1 source company names and 20 product codes. Dated history runs from Oct 19, 1988 to Jun 5, 2018.
| Month | 510(k) decisions | Recall initiations |
|---|---|---|
| October 2025 | 0 | 0 |
| November 2025 | 0 | 0 |
| December 2025 | 0 | 0 |
| January 2026 | 0 | 0 |
| February 2026 | 0 | 0 |
| March 2026 | 0 | 0 |
| April 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| June 2026 | 0 | 0 |
| July 2026 | 0 | 0 |
| August 2026 | 0 | 0 |
| September 2026 | 0 | 0 |
| October 2026 | 0 | 0 |
| Device / record | Company in FDA record | Source | Source date |
|---|---|---|---|
| ImmuGlo HEp-2 Elite IFAK172745 · DHN | Immco Diagnostics, Inc. | 510(k) | Jun 5, 2018FDA decision date |
| ImmuLisa Enhanced RNA POL III Antibody ELISAK172078 · NYO | Immco Diagnostics, Inc. | 510(k) | Mar 30, 2018FDA decision date |
| ImmuLisa Enhanced AMA IgG Antibody ELISA; ImmuLisa Enhanced AMA IgA/IgG/IgM Antibody ELISAK163133 · DBM | Immco Diagnostics, Inc. | 510(k) | Aug 8, 2017FDA decision date |
| ImmuLisa Enhanced Gliadin IgA Antibody ELISA, ImmuLisa Enhanced Gliadin IgG Antibody ELISAK163177 · MST | Immco Diagnostics, Inc. | 510(k) | Jul 28, 2017FDA decision date |
| ImmuLisa Enhanced B2GP1 IgA Antibody ELISA, ImmuLisa Enhanced B2GP1 IgG Antibody ELISA, ImmuLisa Enhanced B2GP1 IgM Antibody ELISA, ImmuLisa Enha…K162788 · MSV | Immco Diagnostics, Inc. | 510(k) | Jun 19, 2017FDA decision date |
| ImmuLisa Enhanced Centromere Antibody ELISAK151559 · LJM | Immco Diagnostics, Inc. | 510(k) | Mar 11, 2016FDA decision date |
| ImmuLisa Enhanced RF IgA Antibody ELISA, ImmuLisa Enhanced RF IgG Antibody ELISA, ImmuLisa Enhanced RF IgM Antibody ELISA, ImmuLisa Enhanced RF A…K143736 · DHR | Immco Diagnostics, Inc. | 510(k) | Sep 23, 2015FDA decision date |
| ImmuLisa Enhanced SS-A (Ro) Antibody ELISA, ImmuLisa Enhanced SS-B (La) Antibody ELISA, ImmuLisa Enhanced Sm Antibody ELISA, ImmuLisa Enhanced RN…K142781 · LLL | Immco Diagnostics, Inc. | 510(k) | Mar 31, 2015FDA decision date |
| IMMULISA ENHANCED CELIAC FUSION (TTG/DGP) IGA/IGG ANTIBODY ELISAK123713 · MVM | Immco Diagnostics, Inc. | 510(k) | Oct 25, 2013FDA decision date |
| IMMULISA ENHANCED (TM) CARDIOLIPIN IGA, IGG, IGM AND IGA/IGG/IGM ANTIBODY (ACA) ELISASK113020 · MID | Immco Diagnostics, Inc. | 510(k) | Oct 25, 2012FDA decision date |
| IMMULISA SCI-70 ANTIBODY ELISAK113143 · LLL | Immco Diagnostics, Inc. | 510(k) | Dec 2, 2011FDA decision date |
| IMMULISA DSDNA ANTIBODY ELISAK101319 · LRM | Immco Diagnostics, Inc. | 510(k) | Dec 9, 2010FDA decision date |
| IMMULISA MPO ANTIBODY ELISAK092599 · MOB | Immco Diagnostics, Inc. | 510(k) | Oct 7, 2010FDA decision date |
| IMMULISA PR3 ANTIBODY ELISAK092600 · MOB | Immco Diagnostics, Inc. | 510(k) | Oct 7, 2010FDA decision date |
| IMMULISA ANCA SCREEN ELISAK092601 · MOB | Immco Diagnostics, Inc. | 510(k) | Oct 7, 2010FDA decision date |
| IMMULISA CELIAC TTG IGA AND IGG ANTIBODY ELISAK091520 · MVM | Immco Diagnostics, Inc. | 510(k) | Mar 10, 2010FDA decision date |
| IMMULISA CELIAC G+ (GLIADIN) IGA AND IGG ANTIBODY ELISAK091522 · MST | Immco Diagnostics, Inc. | 510(k) | Feb 4, 2010FDA decision date |
| IMMULISA INTRINSIC FACTOR ANTIBODY ELISAK071346 · LIG | Immco Diagnostics, Inc. | 510(k) | Sep 24, 2007FDA decision date |
| IMMUGLO ANTI-ENDOMYSIAL ANTIBODY IFAK060157 · MVM | Immco Diagnostics, Inc. | 510(k) | May 25, 2006FDA decision date |
| IMMULISA ANTINUCLEAR ANTIBODY SCREEN ELISAK041102 · LJM | Immco Diagnostics, Inc. | 510(k) | Oct 26, 2004FDA decision date |
| IMMULISA ANTI-SACCHAROMYCES CEREVISIAE ANTIBODY (ASCA) (IGG)K032850 · NBT | Immco Diagnostics, Inc. | 510(k) | Mar 18, 2004FDA decision date |
| IMMULISA ANTI-SACCHAROMYCES CEREVISIAE ANTIBODY (ASCA) (IGA)K032860 · NBT | Immco Diagnostics, Inc. | 510(k) | Mar 18, 2004FDA decision date |
| IMMULISA ANTI-HUMAN TISSUE TRANSGLUTAMINASE (HU-TTG) ANTIBODY TOTAL IGA/IGG ELISAK040095 · MVM | Immco Diagnostics, Inc. | 510(k) | Mar 5, 2004FDA decision date |
| IMMULISA ANTI-HUMAN TISSUE TRANSGLUTAMINASE (HU-TTG) ANTIBODY IGA ELISAK032571 · MVM | Immco Diagnostics, Inc. | 510(k) | Dec 24, 2003FDA decision date |
| IMMULISA ANTI-BETA2 GLYCOPROTEIN I (B2GP1) IGG ELISAK030701 · MSV | Immco Diagnostics, Inc. | 510(k) | Sep 9, 2003FDA decision date |
Check applicant and recalling-firm names without confusing spelling variations, subsidiaries, and unrelated companies.
Read the guide →Build a repeatable clearance search using FDA applicant names, product codes, decision dates, and original records.
Read the guide →FDA dataset:
Last successful check: Nov 22, 2026
Source classifications may change.
FDA dataset:
Last successful check: Nov 22, 2026
FDA publishes this dataset monthly.
FDA dataset:
Last successful check: Nov 22, 2026
FDA publishes this dataset weekly.
Follow ten competitors and ten product codes. Get matching changes in your dashboard and a weekly brief, for $49/month.